Michel Chonchol
Concepts (700)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Insufficiency, Chronic | 86 | 2025 | 617 | 11.700 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 33 | 2025 | 262 | 8.960 |
Why?
| | Kidney Failure, Chronic | 55 | 2023 | 570 | 6.830 |
Why?
| | Glomerular Filtration Rate | 90 | 2025 | 746 | 6.140 |
Why?
| | Renal Dialysis | 33 | 2023 | 435 | 5.290 |
Why?
| | Kidney | 49 | 2025 | 1468 | 5.210 |
Why?
| | Kidney Diseases | 33 | 2025 | 408 | 5.080 |
Why?
| | Fibroblast Growth Factors | 25 | 2020 | 172 | 4.950 |
Why?
| | Cardiovascular Diseases | 57 | 2023 | 2111 | 4.220 |
Why?
| | Vitamin D | 31 | 2022 | 397 | 3.870 |
Why?
| | Hypertension | 37 | 2022 | 1295 | 2.740 |
Why?
| | Vitamin D Deficiency | 13 | 2024 | 186 | 2.660 |
Why?
| | Vascular Stiffness | 19 | 2025 | 494 | 2.430 |
Why?
| | Endothelium, Vascular | 18 | 2025 | 927 | 2.420 |
Why?
| | Phosphates | 12 | 2024 | 182 | 2.370 |
Why?
| | Kidney Calculi | 5 | 2024 | 38 | 2.270 |
Why?
| | Disease Progression | 42 | 2025 | 2757 | 2.190 |
Why?
| | Nutrition Surveys | 15 | 2024 | 266 | 2.160 |
Why?
| | Blood Pressure | 35 | 2023 | 1786 | 2.140 |
Why?
| | Phosphorus | 13 | 2017 | 97 | 2.020 |
Why?
| | Aged | 173 | 2025 | 23961 | 1.980 |
Why?
| | Blood Vessels | 4 | 2024 | 187 | 1.880 |
Why?
| | Middle Aged | 168 | 2025 | 33479 | 1.870 |
Why?
| | Oxidative Stress | 20 | 2025 | 1317 | 1.860 |
Why?
| | Uric Acid | 12 | 2021 | 163 | 1.850 |
Why?
| | Nephrology | 5 | 2022 | 61 | 1.820 |
Why?
| | Male | 231 | 2025 | 67762 | 1.810 |
Why?
| | Humans | 305 | 2025 | 137585 | 1.750 |
Why?
| | Cholecalciferol | 6 | 2024 | 60 | 1.750 |
Why?
| | Female | 231 | 2025 | 73304 | 1.740 |
Why?
| | Creatinine | 25 | 2021 | 499 | 1.700 |
Why?
| | Risk Factors | 90 | 2025 | 10388 | 1.650 |
Why?
| | Sodium, Dietary | 4 | 2024 | 41 | 1.630 |
Why?
| | Inflammation | 21 | 2025 | 2837 | 1.610 |
Why?
| | Potassium, Dietary | 3 | 2024 | 12 | 1.570 |
Why?
| | Chronic Kidney Disease-Mineral and Bone Disorder | 4 | 2020 | 14 | 1.540 |
Why?
| | Parathyroid Hormone | 18 | 2020 | 108 | 1.510 |
Why?
| | Vascular Calcification | 8 | 2022 | 108 | 1.420 |
Why?
| | Double-Blind Method | 30 | 2023 | 1993 | 1.370 |
Why?
| | Dietary Supplements | 10 | 2021 | 561 | 1.360 |
Why?
| | Biomarkers | 45 | 2025 | 4149 | 1.330 |
Why?
| | Brachial Artery | 12 | 2025 | 205 | 1.310 |
Why?
| | Lanthanum | 4 | 2024 | 13 | 1.270 |
Why?
| | Calcium | 13 | 2020 | 1199 | 1.200 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 7 | 2023 | 445 | 1.170 |
Why?
| | Antihypertensive Agents | 14 | 2021 | 494 | 1.150 |
Why?
| | Fatty Liver | 10 | 2013 | 243 | 1.140 |
Why?
| | Adult | 82 | 2025 | 37929 | 1.120 |
Why?
| | Metabolic Syndrome | 7 | 2025 | 354 | 1.080 |
Why?
| | Coronary Disease | 7 | 2010 | 385 | 1.080 |
Why?
| | Naphthalenes | 4 | 2015 | 60 | 1.070 |
Why?
| | Bacterial Infections | 3 | 2016 | 250 | 1.060 |
Why?
| | Pulse Wave Analysis | 12 | 2025 | 272 | 1.050 |
Why?
| | Vasodilation | 8 | 2025 | 499 | 1.040 |
Why?
| | Prevalence | 27 | 2024 | 2734 | 1.040 |
Why?
| | Cross-Sectional Studies | 40 | 2024 | 5472 | 1.030 |
Why?
| | Vascular Diseases | 7 | 2021 | 243 | 0.990 |
Why?
| | Adrenergic beta-Antagonists | 7 | 2011 | 323 | 0.990 |
Why?
| | Coronary Artery Disease | 11 | 2022 | 698 | 0.970 |
Why?
| | Prospective Studies | 41 | 2023 | 7604 | 0.930 |
Why?
| | Hyperparathyroidism, Secondary | 4 | 2009 | 12 | 0.930 |
Why?
| | Cognition | 6 | 2023 | 1153 | 0.910 |
Why?
| | Obesity | 5 | 2025 | 2992 | 0.900 |
Why?
| | Minerals | 6 | 2022 | 42 | 0.880 |
Why?
| | Acute Kidney Injury | 10 | 2022 | 815 | 0.870 |
Why?
| | Cohort Studies | 32 | 2024 | 5742 | 0.850 |
Why?
| | Curcumin | 2 | 2021 | 29 | 0.850 |
Why?
| | Intra-Abdominal Fat | 1 | 2024 | 91 | 0.830 |
Why?
| | Anemia | 5 | 2020 | 170 | 0.800 |
Why?
| | Pregnancy Complications | 3 | 2018 | 527 | 0.800 |
Why?
| | Proportional Hazards Models | 30 | 2019 | 1266 | 0.790 |
Why?
| | Follow-Up Studies | 37 | 2020 | 5131 | 0.790 |
Why?
| | Cognitive Dysfunction | 2 | 2018 | 383 | 0.780 |
Why?
| | Aged, 80 and over | 43 | 2023 | 7635 | 0.780 |
Why?
| | Albuminuria | 13 | 2022 | 185 | 0.770 |
Why?
| | Incidence | 28 | 2021 | 2804 | 0.760 |
Why?
| | Vascular Surgical Procedures | 13 | 2011 | 303 | 0.750 |
Why?
| | Non-alcoholic Fatty Liver Disease | 9 | 2016 | 279 | 0.740 |
Why?
| | Atherosclerosis | 8 | 2021 | 415 | 0.730 |
Why?
| | Metformin | 2 | 2024 | 331 | 0.720 |
Why?
| | Kidney Tubules | 5 | 2024 | 117 | 0.710 |
Why?
| | Kidney Function Tests | 12 | 2017 | 160 | 0.700 |
Why?
| | Renal Insufficiency | 6 | 2023 | 162 | 0.700 |
Why?
| | Calcimimetic Agents | 1 | 2020 | 3 | 0.690 |
Why?
| | Vitamins | 3 | 2022 | 185 | 0.690 |
Why?
| | Hyponatremia | 2 | 2018 | 42 | 0.680 |
Why?
| | Kidney Transplantation | 3 | 2022 | 708 | 0.680 |
Why?
| | Calcitriol | 2 | 2018 | 58 | 0.670 |
Why?
| | Cystatin C | 7 | 2013 | 65 | 0.670 |
Why?
| | Diabetic Nephropathies | 6 | 2025 | 294 | 0.670 |
Why?
| | Sodium | 2 | 2019 | 217 | 0.670 |
Why?
| | Systole | 8 | 2020 | 189 | 0.660 |
Why?
| | Bicarbonates | 5 | 2023 | 44 | 0.660 |
Why?
| | Time Factors | 30 | 2022 | 6828 | 0.660 |
Why?
| | Renal Artery Obstruction | 3 | 2014 | 30 | 0.650 |
Why?
| | Bone Diseases | 1 | 2020 | 62 | 0.650 |
Why?
| | Renin-Angiotensin System | 3 | 2017 | 85 | 0.650 |
Why?
| | Odds Ratio | 13 | 2024 | 1070 | 0.640 |
Why?
| | Sodium Bicarbonate | 2 | 2023 | 45 | 0.630 |
Why?
| | Interleukin-1 | 3 | 2019 | 965 | 0.630 |
Why?
| | Prognosis | 27 | 2021 | 4030 | 0.620 |
Why?
| | Overweight | 2 | 2021 | 558 | 0.610 |
Why?
| | Spironolactone | 1 | 2019 | 36 | 0.600 |
Why?
| | Cause of Death | 6 | 2018 | 434 | 0.600 |
Why?
| | United States | 35 | 2024 | 14841 | 0.600 |
Why?
| | Chronic Disease | 19 | 2017 | 1793 | 0.590 |
Why?
| | Young Adult | 24 | 2025 | 13209 | 0.590 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2019 | 54 | 0.590 |
Why?
| | Treatment Outcome | 38 | 2021 | 10811 | 0.590 |
Why?
| | Simvastatin | 3 | 2014 | 61 | 0.580 |
Why?
| | Heart Diseases | 4 | 2015 | 346 | 0.580 |
Why?
| | Acidosis | 2 | 2018 | 101 | 0.580 |
Why?
| | Hemoglobins | 4 | 2009 | 353 | 0.580 |
Why?
| | Calcium, Dietary | 2 | 2009 | 57 | 0.570 |
Why?
| | Endothelial Cells | 5 | 2023 | 785 | 0.570 |
Why?
| | Accidental Falls | 1 | 2020 | 196 | 0.570 |
Why?
| | Hypertrophy, Left Ventricular | 4 | 2017 | 131 | 0.570 |
Why?
| | Caloric Restriction | 4 | 2024 | 124 | 0.570 |
Why?
| | Death, Sudden, Cardiac | 5 | 2015 | 185 | 0.560 |
Why?
| | Recombinant Fusion Proteins | 2 | 2017 | 665 | 0.560 |
Why?
| | Arterial Pressure | 1 | 2018 | 126 | 0.560 |
Why?
| | Interleukin-6 | 3 | 2020 | 778 | 0.550 |
Why?
| | Frailty | 1 | 2020 | 170 | 0.550 |
Why?
| | Carotid Artery Diseases | 3 | 2021 | 64 | 0.540 |
Why?
| | Calcinosis | 6 | 2017 | 235 | 0.540 |
Why?
| | Multivariate Analysis | 14 | 2017 | 1509 | 0.540 |
Why?
| | Diet | 4 | 2025 | 1278 | 0.530 |
Why?
| | Logistic Models | 12 | 2024 | 2074 | 0.530 |
Why?
| | Longitudinal Studies | 17 | 2020 | 2844 | 0.520 |
Why?
| | Pregnancy Outcome | 3 | 2018 | 416 | 0.520 |
Why?
| | Bone Density | 5 | 2017 | 489 | 0.520 |
Why?
| | Calciphylaxis | 1 | 2016 | 2 | 0.510 |
Why?
| | Conservative Treatment | 1 | 2017 | 33 | 0.510 |
Why?
| | Uremia | 1 | 2016 | 16 | 0.510 |
Why?
| | Sodium Chloride | 1 | 2017 | 142 | 0.500 |
Why?
| | Primary Prevention | 3 | 2018 | 196 | 0.490 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 5 | 2018 | 201 | 0.490 |
Why?
| | Hyperuricemia | 5 | 2018 | 44 | 0.490 |
Why?
| | Fluid Therapy | 1 | 2017 | 147 | 0.480 |
Why?
| | Diet, Sodium-Restricted | 4 | 2020 | 36 | 0.480 |
Why?
| | Myocardial Infarction | 10 | 2017 | 1046 | 0.470 |
Why?
| | Ventricular Dysfunction, Left | 6 | 2014 | 382 | 0.470 |
Why?
| | Peripheral Vascular Diseases | 7 | 2012 | 103 | 0.470 |
Why?
| | Insulin Resistance | 7 | 2025 | 1208 | 0.470 |
Why?
| | Retrospective Studies | 33 | 2024 | 15657 | 0.460 |
Why?
| | Diabetes Mellitus, Type 2 | 10 | 2012 | 2531 | 0.460 |
Why?
| | Diabetes Complications | 6 | 2018 | 227 | 0.460 |
Why?
| | Comorbidity | 13 | 2018 | 1622 | 0.460 |
Why?
| | Undocumented Immigrants | 3 | 2023 | 53 | 0.460 |
Why?
| | Liver | 2 | 2016 | 1943 | 0.450 |
Why?
| | Peripheral Arterial Disease | 7 | 2021 | 475 | 0.450 |
Why?
| | Fructose | 2 | 2016 | 112 | 0.440 |
Why?
| | Risk Assessment | 24 | 2021 | 3457 | 0.440 |
Why?
| | Pyrazoles | 2 | 2014 | 423 | 0.440 |
Why?
| | Survival Rate | 14 | 2020 | 1972 | 0.430 |
Why?
| | Cardiovascular Agents | 4 | 2013 | 159 | 0.430 |
Why?
| | Pyridines | 2 | 2014 | 506 | 0.430 |
Why?
| | Hyperphosphatemia | 4 | 2020 | 15 | 0.420 |
Why?
| | Body Mass Index | 10 | 2024 | 2389 | 0.410 |
Why?
| | Ankle Brachial Index | 4 | 2014 | 37 | 0.410 |
Why?
| | Sodium Nitrite | 3 | 2021 | 39 | 0.410 |
Why?
| | Magnetic Resonance Imaging | 7 | 2024 | 3566 | 0.410 |
Why?
| | Pneumonia, Bacterial | 1 | 2014 | 116 | 0.400 |
Why?
| | C-Reactive Protein | 8 | 2018 | 410 | 0.400 |
Why?
| | TRPP Cation Channels | 5 | 2022 | 85 | 0.390 |
Why?
| | Nephrolithiasis | 1 | 2012 | 11 | 0.390 |
Why?
| | Hemostasis | 2 | 2009 | 82 | 0.380 |
Why?
| | Radius | 1 | 2012 | 39 | 0.380 |
Why?
| | Magnesium | 2 | 2014 | 156 | 0.380 |
Why?
| | Chi-Square Distribution | 10 | 2017 | 530 | 0.380 |
Why?
| | Community-Acquired Infections | 1 | 2014 | 174 | 0.370 |
Why?
| | Carotid Arteries | 4 | 2018 | 206 | 0.370 |
Why?
| | Case-Control Studies | 12 | 2025 | 3556 | 0.370 |
Why?
| | Randomized Controlled Trials as Topic | 11 | 2021 | 1477 | 0.360 |
Why?
| | Heart Ventricles | 2 | 2013 | 788 | 0.360 |
Why?
| | Health Status | 3 | 2015 | 792 | 0.360 |
Why?
| | Coronary Artery Bypass | 3 | 2014 | 234 | 0.350 |
Why?
| | Disease Management | 1 | 2015 | 628 | 0.350 |
Why?
| | Hypothyroidism | 2 | 2009 | 72 | 0.350 |
Why?
| | Independent Living | 5 | 2018 | 105 | 0.350 |
Why?
| | Kaplan-Meier Estimate | 14 | 2018 | 889 | 0.350 |
Why?
| | Internship and Residency | 2 | 2020 | 1147 | 0.350 |
Why?
| | Health Surveys | 3 | 2014 | 514 | 0.350 |
Why?
| | Blood Coagulation Disorders | 2 | 2010 | 173 | 0.350 |
Why?
| | Resistance Training | 2 | 2023 | 164 | 0.340 |
Why?
| | NAD | 2 | 2023 | 77 | 0.340 |
Why?
| | Physical Fitness | 1 | 2012 | 209 | 0.340 |
Why?
| | Dementia | 3 | 2023 | 259 | 0.330 |
Why?
| | Hip Fractures | 3 | 2017 | 86 | 0.330 |
Why?
| | Hypercapnia | 3 | 2025 | 53 | 0.330 |
Why?
| | Homeostasis | 5 | 2018 | 621 | 0.330 |
Why?
| | Ischemia | 3 | 2011 | 409 | 0.320 |
Why?
| | Dyslipidemias | 2 | 2013 | 176 | 0.320 |
Why?
| | Lovastatin | 1 | 2009 | 37 | 0.320 |
Why?
| | Mortality | 5 | 2020 | 362 | 0.320 |
Why?
| | gamma-Glutamyltransferase | 1 | 2009 | 43 | 0.320 |
Why?
| | Zinc | 1 | 2012 | 297 | 0.310 |
Why?
| | Blood Coagulation | 3 | 2011 | 255 | 0.310 |
Why?
| | Polycystic Kidney Diseases | 2 | 2023 | 76 | 0.310 |
Why?
| | Weight Loss | 1 | 2015 | 787 | 0.310 |
Why?
| | Endocrine System Diseases | 1 | 2009 | 35 | 0.310 |
Why?
| | Hospitalization | 3 | 2016 | 2199 | 0.310 |
Why?
| | Fibrinolysis | 2 | 2011 | 146 | 0.310 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 4 | 2024 | 42 | 0.300 |
Why?
| | Hospitals, Veterans | 2 | 2008 | 252 | 0.300 |
Why?
| | Lipocalin-2 | 4 | 2024 | 79 | 0.300 |
Why?
| | Uromodulin | 5 | 2022 | 21 | 0.300 |
Why?
| | Aging | 5 | 2025 | 1864 | 0.300 |
Why?
| | Regional Blood Flow | 5 | 2017 | 474 | 0.300 |
Why?
| | Bilirubin | 1 | 2009 | 97 | 0.300 |
Why?
| | Bone and Bones | 2 | 2012 | 317 | 0.290 |
Why?
| | Phosphorus Metabolism Disorders | 1 | 2007 | 1 | 0.280 |
Why?
| | Severity of Illness Index | 12 | 2020 | 2828 | 0.280 |
Why?
| | Sepsis | 1 | 2014 | 617 | 0.280 |
Why?
| | Patient Navigation | 2 | 2019 | 81 | 0.280 |
Why?
| | Coronary Angiography | 3 | 2012 | 317 | 0.280 |
Why?
| | Aorta | 3 | 2021 | 417 | 0.270 |
Why?
| | Ultrasonography | 6 | 2013 | 759 | 0.260 |
Why?
| | Brain | 2 | 2018 | 2668 | 0.260 |
Why?
| | Metabolomics | 4 | 2022 | 678 | 0.260 |
Why?
| | Aortic Aneurysm, Abdominal | 6 | 2011 | 140 | 0.260 |
Why?
| | Adolescent | 14 | 2023 | 21513 | 0.260 |
Why?
| | Pravastatin | 2 | 2023 | 41 | 0.260 |
Why?
| | Angiotensin Receptor Antagonists | 2 | 2018 | 92 | 0.250 |
Why?
| | Electric Countershock | 1 | 2007 | 107 | 0.250 |
Why?
| | Infant, Low Birth Weight | 2 | 2018 | 141 | 0.250 |
Why?
| | Infant Mortality | 2 | 2018 | 116 | 0.250 |
Why?
| | Professional Competence | 1 | 2006 | 100 | 0.250 |
Why?
| | Coronary Vessels | 3 | 2022 | 248 | 0.240 |
Why?
| | Thrombosis | 1 | 2009 | 371 | 0.240 |
Why?
| | Anticholesteremic Agents | 1 | 2007 | 153 | 0.230 |
Why?
| | Respiratory Muscles | 2 | 2023 | 33 | 0.230 |
Why?
| | Deoxycholic Acid | 3 | 2022 | 14 | 0.230 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2020 | 804 | 0.230 |
Why?
| | Cognition Disorders | 3 | 2017 | 496 | 0.230 |
Why?
| | Fasting | 4 | 2023 | 281 | 0.230 |
Why?
| | Carotid Artery, Internal | 1 | 2025 | 42 | 0.230 |
Why?
| | Pilot Projects | 5 | 2025 | 1710 | 0.230 |
Why?
| | Wine | 1 | 2024 | 12 | 0.230 |
Why?
| | Survival Analysis | 6 | 2019 | 1325 | 0.230 |
Why?
| | Beer | 1 | 2024 | 12 | 0.220 |
Why?
| | Pre-Eclampsia | 2 | 2018 | 190 | 0.220 |
Why?
| | Blood Pressure Determination | 3 | 2020 | 157 | 0.220 |
Why?
| | Tryptophan | 2 | 2023 | 183 | 0.220 |
Why?
| | Nitric Oxide | 5 | 2023 | 915 | 0.220 |
Why?
| | Antidiuretic Hormone Receptor Antagonists | 1 | 2024 | 9 | 0.220 |
Why?
| | Cross-Over Studies | 5 | 2018 | 564 | 0.220 |
Why?
| | Inflammasomes | 1 | 2025 | 131 | 0.220 |
Why?
| | Diabetes Mellitus, Type 1 | 7 | 2014 | 3715 | 0.220 |
Why?
| | Quality of Life | 4 | 2020 | 2892 | 0.210 |
Why?
| | Linear Models | 6 | 2017 | 849 | 0.210 |
Why?
| | Cerebrovascular Circulation | 3 | 2025 | 243 | 0.210 |
Why?
| | Obesity, Abdominal | 1 | 2024 | 48 | 0.210 |
Why?
| | Nephrotic Syndrome | 1 | 2003 | 39 | 0.210 |
Why?
| | Terminology as Topic | 1 | 2025 | 216 | 0.210 |
Why?
| | Diet, Ketogenic | 1 | 2023 | 37 | 0.210 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2020 | 350 | 0.210 |
Why?
| | Nutritional Status | 2 | 2018 | 350 | 0.210 |
Why?
| | Confidence Intervals | 3 | 2012 | 329 | 0.200 |
Why?
| | Mitochondria | 2 | 2021 | 948 | 0.200 |
Why?
| | Military Personnel | 1 | 2009 | 544 | 0.200 |
Why?
| | Atrial Fibrillation | 2 | 2020 | 388 | 0.200 |
Why?
| | Metabolome | 3 | 2022 | 350 | 0.200 |
Why?
| | Animals | 15 | 2023 | 36940 | 0.200 |
Why?
| | Drug Therapy, Combination | 6 | 2020 | 1066 | 0.200 |
Why?
| | Human Umbilical Vein Endothelial Cells | 2 | 2021 | 107 | 0.200 |
Why?
| | Recovery of Function | 3 | 2017 | 653 | 0.200 |
Why?
| | Colorado | 9 | 2021 | 4565 | 0.190 |
Why?
| | Compassion Fatigue | 1 | 2022 | 31 | 0.190 |
Why?
| | Up-Regulation | 5 | 2019 | 843 | 0.190 |
Why?
| | Age Factors | 9 | 2025 | 3295 | 0.190 |
Why?
| | Antioxidants | 2 | 2018 | 584 | 0.190 |
Why?
| | Troponin T | 3 | 2012 | 65 | 0.190 |
Why?
| | Receptor Protein-Tyrosine Kinases | 2 | 2014 | 234 | 0.190 |
Why?
| | Diastole | 3 | 2013 | 149 | 0.190 |
Why?
| | Guideline Adherence | 1 | 2006 | 556 | 0.190 |
Why?
| | Child | 9 | 2023 | 21935 | 0.190 |
Why?
| | Physicians | 2 | 2022 | 910 | 0.180 |
Why?
| | Heart Failure | 8 | 2017 | 2236 | 0.180 |
Why?
| | Breathing Exercises | 1 | 2021 | 21 | 0.180 |
Why?
| | Inhalation | 1 | 2021 | 29 | 0.180 |
Why?
| | Exercise Tolerance | 1 | 2023 | 279 | 0.180 |
Why?
| | Niacinamide | 2 | 2020 | 82 | 0.180 |
Why?
| | Toxins, Biological | 1 | 2020 | 12 | 0.170 |
Why?
| | Predictive Value of Tests | 11 | 2019 | 2031 | 0.170 |
Why?
| | Diabetes Mellitus | 4 | 2020 | 1040 | 0.170 |
Why?
| | Parathyroidectomy | 1 | 2020 | 9 | 0.170 |
Why?
| | Education | 2 | 2018 | 108 | 0.170 |
Why?
| | Culturally Competent Care | 1 | 2021 | 63 | 0.170 |
Why?
| | Stroke | 4 | 2017 | 1120 | 0.170 |
Why?
| | Osteoporotic Fractures | 2 | 2012 | 60 | 0.170 |
Why?
| | Propensity Score | 2 | 2019 | 294 | 0.170 |
Why?
| | Intestinal Absorption | 1 | 2021 | 102 | 0.170 |
Why?
| | Propanolamines | 2 | 2011 | 96 | 0.170 |
Why?
| | Neutrophils | 1 | 2006 | 1238 | 0.170 |
Why?
| | Motor Activity | 2 | 2015 | 718 | 0.170 |
Why?
| | Sevelamer | 1 | 2020 | 9 | 0.170 |
Why?
| | Netherlands | 8 | 2012 | 88 | 0.170 |
Why?
| | Carotid Intima-Media Thickness | 2 | 2018 | 90 | 0.170 |
Why?
| | Allopurinol | 2 | 2018 | 63 | 0.170 |
Why?
| | Placebos | 2 | 2012 | 199 | 0.170 |
Why?
| | Plaque, Atherosclerotic | 1 | 2021 | 57 | 0.170 |
Why?
| | Communication Barriers | 1 | 2021 | 104 | 0.170 |
Why?
| | Hypokalemia | 1 | 2020 | 24 | 0.170 |
Why?
| | Attitude of Health Personnel | 2 | 2018 | 1171 | 0.160 |
Why?
| | Feasibility Studies | 2 | 2021 | 956 | 0.160 |
Why?
| | Hyperkalemia | 1 | 2020 | 24 | 0.160 |
Why?
| | Tunica Intima | 3 | 2010 | 84 | 0.160 |
Why?
| | Socioeconomic Factors | 3 | 2020 | 1289 | 0.160 |
Why?
| | Organ Size | 2 | 2017 | 477 | 0.160 |
Why?
| | Acetates | 1 | 2020 | 99 | 0.160 |
Why?
| | Ambulatory Care Facilities | 1 | 2021 | 232 | 0.160 |
Why?
| | Age Distribution | 2 | 2012 | 392 | 0.160 |
Why?
| | Inflammation Mediators | 2 | 2025 | 513 | 0.160 |
Why?
| | Preoperative Period | 4 | 2014 | 129 | 0.160 |
Why?
| | Sex Distribution | 2 | 2012 | 375 | 0.160 |
Why?
| | Energy Metabolism | 2 | 2024 | 922 | 0.160 |
Why?
| | Focus Groups | 2 | 2020 | 522 | 0.150 |
Why?
| | Patient Care Planning | 1 | 2020 | 157 | 0.150 |
Why?
| | Adiposity | 1 | 2024 | 518 | 0.150 |
Why?
| | Neuroimaging | 2 | 2018 | 259 | 0.150 |
Why?
| | Lipoproteins, HDL | 1 | 2019 | 77 | 0.150 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2020 | 153 | 0.150 |
Why?
| | Calcification, Physiologic | 1 | 2018 | 32 | 0.150 |
Why?
| | Immunosuppressive Agents | 1 | 2003 | 890 | 0.150 |
Why?
| | Potassium | 2 | 2020 | 147 | 0.140 |
Why?
| | Carnitine | 1 | 2018 | 84 | 0.140 |
Why?
| | Information Seeking Behavior | 1 | 2018 | 34 | 0.140 |
Why?
| | Scandinavian and Nordic Countries | 2 | 2008 | 13 | 0.140 |
Why?
| | Electrocardiography | 5 | 2020 | 629 | 0.140 |
Why?
| | Reactive Oxygen Species | 4 | 2023 | 622 | 0.140 |
Why?
| | Pain | 2 | 2020 | 756 | 0.140 |
Why?
| | Infant, Newborn | 4 | 2018 | 6079 | 0.140 |
Why?
| | Cholesterol, HDL | 4 | 2013 | 203 | 0.140 |
Why?
| | Mice | 8 | 2023 | 17787 | 0.140 |
Why?
| | Sex Factors | 6 | 2025 | 2071 | 0.140 |
Why?
| | Healthy Lifestyle | 1 | 2018 | 34 | 0.140 |
Why?
| | Fellowships and Scholarships | 2 | 2020 | 306 | 0.140 |
Why?
| | Healthy Aging | 1 | 2018 | 35 | 0.140 |
Why?
| | Alcohol Drinking | 1 | 2024 | 828 | 0.140 |
Why?
| | Bone Diseases, Metabolic | 1 | 2018 | 63 | 0.140 |
Why?
| | Adaptive Immunity | 1 | 2018 | 165 | 0.140 |
Why?
| | Postoperative Complications | 6 | 2014 | 2654 | 0.130 |
Why?
| | Emergency Treatment | 1 | 2018 | 118 | 0.130 |
Why?
| | Femoral Artery | 1 | 2018 | 179 | 0.130 |
Why?
| | Hemodialysis Solutions | 1 | 2017 | 3 | 0.130 |
Why?
| | Death | 1 | 2018 | 119 | 0.130 |
Why?
| | Health Services Accessibility | 3 | 2021 | 986 | 0.130 |
Why?
| | Peer Group | 1 | 2019 | 242 | 0.130 |
Why?
| | Preoperative Care | 2 | 2010 | 362 | 0.130 |
Why?
| | 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 2 | 2013 | 17 | 0.130 |
Why?
| | Vasopressins | 1 | 2017 | 64 | 0.130 |
Why?
| | Immunity, Humoral | 1 | 2017 | 116 | 0.130 |
Why?
| | Neuropsychological Tests | 2 | 2018 | 1023 | 0.130 |
Why?
| | Congenital Abnormalities | 1 | 2017 | 92 | 0.130 |
Why?
| | Living Donors | 1 | 2018 | 295 | 0.130 |
Why?
| | Trehalose | 1 | 2016 | 32 | 0.130 |
Why?
| | Postoperative Period | 3 | 2011 | 342 | 0.120 |
Why?
| | Cholesterol, LDL | 3 | 2013 | 365 | 0.120 |
Why?
| | Burnout, Professional | 1 | 2022 | 442 | 0.120 |
Why?
| | Liver Transplantation | 1 | 2003 | 871 | 0.120 |
Why?
| | Bile Acids and Salts | 1 | 2017 | 200 | 0.120 |
Why?
| | Lipogenesis | 1 | 2016 | 61 | 0.120 |
Why?
| | Vascular Resistance | 2 | 2014 | 375 | 0.120 |
Why?
| | Heart Arrest | 2 | 2016 | 339 | 0.120 |
Why?
| | Heart Valve Diseases | 1 | 2017 | 151 | 0.120 |
Why?
| | Mutation | 3 | 2022 | 3958 | 0.120 |
Why?
| | Absorptiometry, Photon | 2 | 2017 | 259 | 0.120 |
Why?
| | Heart Rate | 2 | 2011 | 822 | 0.120 |
Why?
| | Immunity, Cellular | 1 | 2017 | 268 | 0.120 |
Why?
| | Stearoyl-CoA Desaturase | 1 | 2015 | 65 | 0.120 |
Why?
| | Risk Reduction Behavior | 2 | 2015 | 220 | 0.120 |
Why?
| | Phosphatidylethanolamines | 1 | 2015 | 77 | 0.120 |
Why?
| | Pregnancy | 3 | 2018 | 6763 | 0.120 |
Why?
| | Communicable Diseases | 1 | 2017 | 159 | 0.120 |
Why?
| | Analysis of Variance | 3 | 2012 | 1316 | 0.120 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2015 | 110 | 0.120 |
Why?
| | Obstetric Labor, Premature | 1 | 2015 | 36 | 0.110 |
Why?
| | Frail Elderly | 1 | 2016 | 131 | 0.110 |
Why?
| | Global Health | 2 | 2015 | 386 | 0.110 |
Why?
| | Maternal Mortality | 1 | 2015 | 46 | 0.110 |
Why?
| | Aorta, Abdominal | 2 | 2012 | 46 | 0.110 |
Why?
| | Risk | 5 | 2019 | 912 | 0.110 |
Why?
| | Fibroblast Growth Factor 3 | 1 | 2014 | 3 | 0.110 |
Why?
| | Metabolic Diseases | 2 | 2014 | 108 | 0.110 |
Why?
| | Peptides | 1 | 2020 | 985 | 0.110 |
Why?
| | Serine | 1 | 2015 | 141 | 0.110 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2013 | 2057 | 0.110 |
Why?
| | Italy | 5 | 2014 | 110 | 0.110 |
Why?
| | 24,25-Dihydroxyvitamin D 3 | 1 | 2014 | 3 | 0.110 |
Why?
| | Acetylcholine | 3 | 2023 | 185 | 0.110 |
Why?
| | Transcription Factor CHOP | 1 | 2014 | 31 | 0.110 |
Why?
| | Renal Artery | 1 | 2014 | 37 | 0.110 |
Why?
| | Estrogen Replacement Therapy | 2 | 2014 | 146 | 0.110 |
Why?
| | Urinary Tract Infections | 1 | 2016 | 188 | 0.110 |
Why?
| | Transforming Growth Factor beta | 1 | 2017 | 480 | 0.110 |
Why?
| | Organophosphonates | 1 | 2014 | 93 | 0.110 |
Why?
| | Infant, Small for Gestational Age | 1 | 2015 | 92 | 0.110 |
Why?
| | Linoleic Acids, Conjugated | 1 | 2013 | 8 | 0.110 |
Why?
| | Endothelium | 1 | 2014 | 123 | 0.110 |
Why?
| | Sodium Chloride, Dietary | 1 | 2014 | 36 | 0.110 |
Why?
| | Tocopherols | 1 | 2013 | 26 | 0.110 |
Why?
| | Steroid Hydroxylases | 1 | 2013 | 22 | 0.110 |
Why?
| | NF-kappa B p50 Subunit | 1 | 2013 | 26 | 0.110 |
Why?
| | Bufanolides | 1 | 2013 | 4 | 0.110 |
Why?
| | Aortic Valve Stenosis | 2 | 2017 | 229 | 0.110 |
Why?
| | Antibodies, Monoclonal | 1 | 2020 | 1430 | 0.100 |
Why?
| | Observational Studies as Topic | 1 | 2014 | 117 | 0.100 |
Why?
| | Statistics as Topic | 2 | 2017 | 307 | 0.100 |
Why?
| | Cesarean Section | 1 | 2015 | 184 | 0.100 |
Why?
| | Premature Birth | 1 | 2017 | 333 | 0.100 |
Why?
| | Glucose | 1 | 2018 | 1020 | 0.100 |
Why?
| | Enzyme Inhibitors | 1 | 2016 | 840 | 0.100 |
Why?
| | Healthcare Disparities | 1 | 2019 | 654 | 0.100 |
Why?
| | Education, Medical, Graduate | 1 | 2017 | 486 | 0.100 |
Why?
| | Gastrointestinal Microbiome | 1 | 2020 | 697 | 0.100 |
Why?
| | Spinal Fractures | 1 | 2013 | 73 | 0.100 |
Why?
| | Adenine | 1 | 2014 | 271 | 0.100 |
Why?
| | Institutionalization | 1 | 2012 | 13 | 0.100 |
Why?
| | Ferric Compounds | 1 | 2012 | 56 | 0.100 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2018 | 900 | 0.090 |
Why?
| | Causality | 2 | 2011 | 126 | 0.090 |
Why?
| | Glycation End Products, Advanced | 1 | 2012 | 82 | 0.090 |
Why?
| | Chitinase-3-Like Protein 1 | 2 | 2024 | 19 | 0.090 |
Why?
| | Endoplasmic Reticulum | 1 | 2014 | 265 | 0.090 |
Why?
| | Aortic Aneurysm | 1 | 2012 | 64 | 0.090 |
Why?
| | Tunica Media | 2 | 2010 | 38 | 0.090 |
Why?
| | Kynurenine | 2 | 2023 | 114 | 0.090 |
Why?
| | Postoperative Care | 2 | 2010 | 261 | 0.090 |
Why?
| | Sympathetic Nervous System | 2 | 2015 | 182 | 0.090 |
Why?
| | Echocardiography, Stress | 2 | 2010 | 25 | 0.090 |
Why?
| | Cytokines | 2 | 2018 | 2085 | 0.090 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2015 | 257 | 0.090 |
Why?
| | Dietary Fiber | 1 | 2011 | 54 | 0.090 |
Why?
| | Chemokine CCL2 | 2 | 2024 | 115 | 0.090 |
Why?
| | Meta-Analysis as Topic | 1 | 2012 | 186 | 0.090 |
Why?
| | Hemostatic Disorders | 1 | 2011 | 1 | 0.090 |
Why?
| | International Classification of Diseases | 1 | 2012 | 135 | 0.090 |
Why?
| | Hospital Mortality | 2 | 2014 | 911 | 0.090 |
Why?
| | Models, Biological | 3 | 2024 | 1783 | 0.090 |
Why?
| | Drug Combinations | 1 | 2012 | 343 | 0.090 |
Why?
| | Lung Neoplasms | 2 | 2014 | 2526 | 0.090 |
Why?
| | Cardiovascular System | 3 | 2020 | 137 | 0.090 |
Why?
| | Heart Failure, Systolic | 1 | 2010 | 25 | 0.090 |
Why?
| | Muscle Strength | 2 | 2023 | 317 | 0.080 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2010 | 99 | 0.080 |
Why?
| | Carbazoles | 1 | 2010 | 83 | 0.080 |
Why?
| | Gout | 1 | 2010 | 37 | 0.080 |
Why?
| | Infant, Premature | 1 | 2015 | 574 | 0.080 |
Why?
| | Ticlopidine | 1 | 2010 | 52 | 0.080 |
Why?
| | Thinness | 1 | 2010 | 91 | 0.080 |
Why?
| | Alpha-Globulins | 2 | 2020 | 20 | 0.080 |
Why?
| | Aneurysm | 1 | 2009 | 31 | 0.080 |
Why?
| | beta 2-Microglobulin | 2 | 2020 | 50 | 0.080 |
Why?
| | Proteinuria | 2 | 2014 | 97 | 0.080 |
Why?
| | Nisoldipine | 1 | 2009 | 7 | 0.080 |
Why?
| | Enalapril | 1 | 2009 | 16 | 0.080 |
Why?
| | Arterial Occlusive Diseases | 1 | 2009 | 83 | 0.080 |
Why?
| | Genetic Loci | 1 | 2010 | 288 | 0.080 |
Why?
| | Length of Stay | 1 | 2015 | 1215 | 0.080 |
Why?
| | Cerebrovascular Disorders | 1 | 2009 | 96 | 0.080 |
Why?
| | Texas | 1 | 2009 | 244 | 0.080 |
Why?
| | Radioisotope Renography | 1 | 2008 | 4 | 0.080 |
Why?
| | Mice, Inbred C57BL | 4 | 2023 | 5757 | 0.080 |
Why?
| | Regression Analysis | 3 | 2019 | 1024 | 0.070 |
Why?
| | Ultrasonography, Doppler, Color | 1 | 2008 | 39 | 0.070 |
Why?
| | Thrombophilia | 1 | 2009 | 83 | 0.070 |
Why?
| | Tomography, Spiral Computed | 1 | 2008 | 32 | 0.070 |
Why?
| | Delphi Technique | 2 | 2020 | 280 | 0.070 |
Why?
| | Population Groups | 1 | 2009 | 62 | 0.070 |
Why?
| | Chelating Agents | 2 | 2020 | 75 | 0.070 |
Why?
| | Qualitative Research | 3 | 2021 | 1386 | 0.070 |
Why?
| | Databases as Topic | 1 | 2008 | 67 | 0.070 |
Why?
| | Perindopril | 1 | 2007 | 1 | 0.070 |
Why?
| | Demography | 1 | 2009 | 291 | 0.070 |
Why?
| | Diabetic Retinopathy | 1 | 2010 | 189 | 0.070 |
Why?
| | Osteogenesis | 2 | 2021 | 188 | 0.070 |
Why?
| | Infant | 3 | 2018 | 9465 | 0.070 |
Why?
| | Protein Kinase Inhibitors | 1 | 2013 | 916 | 0.070 |
Why?
| | Endpoint Determination | 1 | 2008 | 77 | 0.070 |
Why?
| | Adenocarcinoma | 1 | 2014 | 940 | 0.070 |
Why?
| | Aspirin | 1 | 2010 | 387 | 0.070 |
Why?
| | Data Interpretation, Statistical | 1 | 2009 | 363 | 0.070 |
Why?
| | Mice, Knockout | 3 | 2023 | 3015 | 0.070 |
Why?
| | Peptide Fragments | 1 | 2010 | 706 | 0.060 |
Why?
| | Estradiol | 1 | 2010 | 521 | 0.060 |
Why?
| | Magnetic Resonance Angiography | 1 | 2008 | 240 | 0.060 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2010 | 463 | 0.060 |
Why?
| | Testosterone | 1 | 2010 | 409 | 0.060 |
Why?
| | Forearm | 2 | 2017 | 119 | 0.060 |
Why?
| | Sodium-Glucose Transporter 2 | 1 | 2025 | 24 | 0.060 |
Why?
| | Triglycerides | 3 | 2013 | 524 | 0.060 |
Why?
| | Protective Factors | 2 | 2016 | 93 | 0.060 |
Why?
| | Contrast Media | 1 | 2008 | 467 | 0.060 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2013 | 1081 | 0.060 |
Why?
| | Middle Cerebral Artery | 1 | 2025 | 53 | 0.060 |
Why?
| | Calcifediol | 1 | 2024 | 33 | 0.060 |
Why?
| | Immunity, Innate | 1 | 2011 | 828 | 0.060 |
Why?
| | Outpatients | 1 | 2008 | 396 | 0.060 |
Why?
| | Autoimmune Diseases | 1 | 2009 | 460 | 0.060 |
Why?
| | Vegetables | 1 | 2025 | 157 | 0.060 |
Why?
| | Phagocytosis | 1 | 2006 | 380 | 0.050 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2024 | 70 | 0.050 |
Why?
| | Genotype | 2 | 2020 | 1916 | 0.050 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2016 | 852 | 0.050 |
Why?
| | Hemodialysis, Home | 1 | 2023 | 8 | 0.050 |
Why?
| | Nicotinamide Mononucleotide | 1 | 2023 | 9 | 0.050 |
Why?
| | Respiratory Therapy | 1 | 2023 | 23 | 0.050 |
Why?
| | Ascorbic Acid | 1 | 2025 | 177 | 0.050 |
Why?
| | Self-Help Groups | 1 | 2023 | 35 | 0.050 |
Why?
| | B7-1 Antigen | 1 | 2023 | 58 | 0.050 |
Why?
| | Postmenopause | 1 | 2025 | 366 | 0.050 |
Why?
| | Cysts | 1 | 2024 | 113 | 0.050 |
Why?
| | Ultrasonography, Doppler | 1 | 2003 | 124 | 0.050 |
Why?
| | Kidney Glomerulus | 1 | 2003 | 119 | 0.050 |
Why?
| | Tryptophan Oxygenase | 1 | 2023 | 34 | 0.050 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2023 | 56 | 0.050 |
Why?
| | Hand Strength | 1 | 2023 | 123 | 0.050 |
Why?
| | Muscles | 1 | 2023 | 326 | 0.050 |
Why?
| | Caregivers | 2 | 2020 | 877 | 0.050 |
Why?
| | NADPH Oxidases | 2 | 2013 | 113 | 0.050 |
Why?
| | Antineoplastic Agents | 1 | 2013 | 2129 | 0.050 |
Why?
| | Least-Squares Analysis | 2 | 2012 | 79 | 0.050 |
Why?
| | Administration, Oral | 1 | 2024 | 816 | 0.050 |
Why?
| | Midazolam | 1 | 2022 | 56 | 0.050 |
Why?
| | Waist Circumference | 2 | 2012 | 143 | 0.050 |
Why?
| | Blood Flow Velocity | 1 | 2023 | 413 | 0.050 |
Why?
| | Vulnerable Populations | 1 | 2022 | 163 | 0.050 |
Why?
| | Mice, Mutant Strains | 1 | 2022 | 298 | 0.040 |
Why?
| | Activating Transcription Factor 4 | 1 | 2021 | 20 | 0.040 |
Why?
| | Carbon Dioxide | 1 | 2023 | 267 | 0.040 |
Why?
| | Endocannabinoids | 1 | 2022 | 63 | 0.040 |
Why?
| | B7-H1 Antigen | 1 | 2023 | 217 | 0.040 |
Why?
| | Social Isolation | 1 | 2021 | 62 | 0.040 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2009 | 1040 | 0.040 |
Why?
| | Hematinics | 1 | 2020 | 22 | 0.040 |
Why?
| | Hepcidins | 1 | 2020 | 22 | 0.040 |
Why?
| | Clinical Trials as Topic | 2 | 2019 | 1050 | 0.040 |
Why?
| | Databases, Genetic | 1 | 2022 | 237 | 0.040 |
Why?
| | Nephrologists | 1 | 2020 | 13 | 0.040 |
Why?
| | Administrative Personnel | 1 | 2020 | 29 | 0.040 |
Why?
| | Acute Disease | 2 | 2017 | 1007 | 0.040 |
Why?
| | Phenotype | 2 | 2022 | 3196 | 0.040 |
Why?
| | Calcium Compounds | 1 | 2020 | 5 | 0.040 |
Why?
| | Asia | 1 | 2020 | 71 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2023 | 1236 | 0.040 |
Why?
| | Hypoglycemic Agents | 2 | 2024 | 1291 | 0.040 |
Why?
| | Africa | 1 | 2020 | 108 | 0.040 |
Why?
| | Serum Albumin | 1 | 2020 | 150 | 0.040 |
Why?
| | California | 2 | 2012 | 431 | 0.040 |
Why?
| | Biopsy | 1 | 2003 | 1129 | 0.040 |
Why?
| | Vitamin B Complex | 1 | 2020 | 44 | 0.040 |
Why?
| | Magnetic Resonance Imaging, Cine | 1 | 2021 | 193 | 0.040 |
Why?
| | HIV Infections | 1 | 2014 | 2836 | 0.040 |
Why?
| | Disease Models, Animal | 2 | 2022 | 4295 | 0.040 |
Why?
| | Social Stigma | 1 | 2021 | 137 | 0.040 |
Why?
| | Stakeholder Participation | 1 | 2020 | 78 | 0.040 |
Why?
| | Matched-Pair Analysis | 1 | 2019 | 39 | 0.040 |
Why?
| | Drug Monitoring | 1 | 2021 | 218 | 0.040 |
Why?
| | Drug Interactions | 1 | 2021 | 410 | 0.040 |
Why?
| | Health Literacy | 1 | 2021 | 168 | 0.040 |
Why?
| | Models, Animal | 1 | 2021 | 384 | 0.040 |
Why?
| | Intracranial Aneurysm | 1 | 2020 | 97 | 0.040 |
Why?
| | Glucuronidase | 1 | 2018 | 44 | 0.040 |
Why?
| | Registries | 2 | 2021 | 2035 | 0.040 |
Why?
| | Tandem Mass Spectrometry | 1 | 2022 | 532 | 0.040 |
Why?
| | Renal Circulation | 1 | 2018 | 58 | 0.040 |
Why?
| | Ligands | 1 | 2020 | 664 | 0.040 |
Why?
| | Patients | 1 | 2020 | 175 | 0.040 |
Why?
| | Symptom Flare Up | 1 | 2018 | 39 | 0.040 |
Why?
| | Urban Population | 1 | 2021 | 479 | 0.040 |
Why?
| | Sodium Chloride Symporter Inhibitors | 1 | 2018 | 8 | 0.040 |
Why?
| | Aftercare | 1 | 2020 | 208 | 0.040 |
Why?
| | Career Choice | 1 | 2020 | 219 | 0.040 |
Why?
| | Self Concept | 1 | 2020 | 253 | 0.040 |
Why?
| | Pyridinium Compounds | 1 | 2018 | 28 | 0.040 |
Why?
| | Publications | 1 | 2018 | 47 | 0.040 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2019 | 151 | 0.040 |
Why?
| | Fathers | 1 | 2018 | 50 | 0.030 |
Why?
| | Intelligence Tests | 1 | 2017 | 57 | 0.030 |
Why?
| | Healthy Volunteers | 1 | 2018 | 199 | 0.030 |
Why?
| | Mitral Valve Stenosis | 1 | 2017 | 18 | 0.030 |
Why?
| | Fibrosis | 1 | 2020 | 552 | 0.030 |
Why?
| | NF-kappa B | 2 | 2012 | 691 | 0.030 |
Why?
| | Interleukin-18 | 1 | 2018 | 236 | 0.030 |
Why?
| | Calcium Channel Blockers | 1 | 2018 | 167 | 0.030 |
Why?
| | Cholesterol | 1 | 2019 | 410 | 0.030 |
Why?
| | Femur Neck | 1 | 2017 | 61 | 0.030 |
Why?
| | Consensus | 1 | 2020 | 683 | 0.030 |
Why?
| | Activities of Daily Living | 1 | 2020 | 413 | 0.030 |
Why?
| | Energy Intake | 1 | 2020 | 485 | 0.030 |
Why?
| | Safety-net Providers | 1 | 2018 | 119 | 0.030 |
Why?
| | Diuretics | 1 | 2016 | 74 | 0.030 |
Why?
| | Quality of Health Care | 1 | 2021 | 642 | 0.030 |
Why?
| | Patient Reported Outcome Measures | 1 | 2020 | 402 | 0.030 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2018 | 190 | 0.030 |
Why?
| | Methemoglobin | 1 | 2015 | 21 | 0.030 |
Why?
| | Sensitivity and Specificity | 2 | 2010 | 1946 | 0.030 |
Why?
| | Program Development | 1 | 2018 | 364 | 0.030 |
Why?
| | Hip Joint | 1 | 2017 | 171 | 0.030 |
Why?
| | Chromatography, Liquid | 1 | 2017 | 433 | 0.030 |
Why?
| | Anthropometry | 1 | 2016 | 213 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2022 | 951 | 0.030 |
Why?
| | White Matter | 1 | 2017 | 145 | 0.030 |
Why?
| | Research | 1 | 2018 | 451 | 0.030 |
Why?
| | Elasticity | 1 | 2015 | 197 | 0.030 |
Why?
| | Renal Reabsorption | 1 | 2014 | 4 | 0.030 |
Why?
| | Gastrointestinal Absorption | 1 | 2014 | 5 | 0.030 |
Why?
| | Urinalysis | 1 | 2015 | 77 | 0.030 |
Why?
| | Renal Elimination | 1 | 2014 | 6 | 0.030 |
Why?
| | Interviews as Topic | 1 | 2018 | 786 | 0.030 |
Why?
| | Vasodilator Agents | 1 | 2017 | 331 | 0.030 |
Why?
| | Ketocholesterols | 1 | 2014 | 7 | 0.030 |
Why?
| | Age of Onset | 1 | 2016 | 518 | 0.030 |
Why?
| | France | 1 | 2014 | 33 | 0.030 |
Why?
| | Prenatal Diagnosis | 1 | 2016 | 201 | 0.030 |
Why?
| | Actigraphy | 1 | 2015 | 110 | 0.030 |
Why?
| | Patient Satisfaction | 1 | 2019 | 660 | 0.030 |
Why?
| | Ultrasonography, Doppler, Duplex | 1 | 2014 | 43 | 0.030 |
Why?
| | Ezetimibe | 1 | 2014 | 24 | 0.030 |
Why?
| | Needs Assessment | 1 | 2017 | 376 | 0.030 |
Why?
| | Prostaglandins | 1 | 2014 | 97 | 0.030 |
Why?
| | Dilatation, Pathologic | 1 | 2014 | 62 | 0.030 |
Why?
| | Azetidines | 1 | 2014 | 43 | 0.030 |
Why?
| | Research Design | 2 | 2011 | 1139 | 0.030 |
Why?
| | Societies, Medical | 1 | 2018 | 820 | 0.030 |
Why?
| | Osteoporosis | 1 | 2017 | 243 | 0.030 |
Why?
| | Apolipoproteins E | 1 | 2014 | 83 | 0.030 |
Why?
| | F2-Isoprostanes | 1 | 2013 | 21 | 0.030 |
Why?
| | Aortic Valve | 1 | 2017 | 351 | 0.030 |
Why?
| | Arachidonate 12-Lipoxygenase | 1 | 2013 | 18 | 0.030 |
Why?
| | Early Medical Intervention | 1 | 2014 | 57 | 0.030 |
Why?
| | Arachidonate 15-Lipoxygenase | 1 | 2013 | 23 | 0.030 |
Why?
| | Acute Coronary Syndrome | 1 | 2017 | 279 | 0.030 |
Why?
| | Erythropoiesis | 1 | 2013 | 55 | 0.030 |
Why?
| | Immunotherapy | 1 | 2018 | 641 | 0.030 |
Why?
| | Health Personnel | 1 | 2020 | 710 | 0.030 |
Why?
| | Pulse | 1 | 2013 | 23 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2021 | 4193 | 0.030 |
Why?
| | Program Evaluation | 1 | 2018 | 898 | 0.030 |
Why?
| | Immunoblotting | 1 | 2013 | 308 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2018 | 2167 | 0.030 |
Why?
| | Signal Transduction | 2 | 2018 | 5079 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2022 | 2426 | 0.030 |
Why?
| | Executive Function | 1 | 2018 | 451 | 0.030 |
Why?
| | Tenofovir | 1 | 2014 | 243 | 0.020 |
Why?
| | Albumins | 1 | 2013 | 114 | 0.020 |
Why?
| | Random Allocation | 1 | 2013 | 353 | 0.020 |
Why?
| | Cell Line | 1 | 2018 | 2847 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2013 | 390 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2014 | 786 | 0.020 |
Why?
| | Biological Availability | 1 | 2012 | 148 | 0.020 |
Why?
| | Xanthine Oxidase | 1 | 2012 | 81 | 0.020 |
Why?
| | Aspartate Aminotransferases | 1 | 2012 | 90 | 0.020 |
Why?
| | Germany | 1 | 2012 | 121 | 0.020 |
Why?
| | Blood Glucose | 2 | 2012 | 2186 | 0.020 |
Why?
| | Microcirculation | 1 | 2012 | 149 | 0.020 |
Why?
| | Epithelial Cells | 1 | 2018 | 1096 | 0.020 |
Why?
| | Ventricular Remodeling | 1 | 2014 | 266 | 0.020 |
Why?
| | Insulin | 2 | 2013 | 2409 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2013 | 1092 | 0.020 |
Why?
| | Stress, Psychological | 1 | 2020 | 1100 | 0.020 |
Why?
| | Mothers | 1 | 2018 | 754 | 0.020 |
Why?
| | Lipoproteins, LDL | 1 | 2012 | 116 | 0.020 |
Why?
| | Metoprolol | 1 | 2011 | 40 | 0.020 |
Why?
| | Perioperative Period | 1 | 2011 | 56 | 0.020 |
Why?
| | Nitroglycerin | 1 | 2010 | 17 | 0.020 |
Why?
| | Aortic Diseases | 1 | 2012 | 119 | 0.020 |
Why?
| | Salicylates | 1 | 2010 | 28 | 0.020 |
Why?
| | Genetic Association Studies | 1 | 2012 | 377 | 0.020 |
Why?
| | Arteries | 1 | 2012 | 269 | 0.020 |
Why?
| | Receptors, Calcitriol | 1 | 2010 | 55 | 0.020 |
Why?
| | Stroke Volume | 1 | 2013 | 612 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2011 | 413 | 0.020 |
Why?
| | Sunlight | 1 | 2010 | 73 | 0.020 |
Why?
| | Area Under Curve | 1 | 2010 | 314 | 0.020 |
Why?
| | Lipids | 1 | 2014 | 672 | 0.020 |
Why?
| | Superoxide Dismutase | 1 | 2012 | 346 | 0.020 |
Why?
| | Life Style | 1 | 2012 | 490 | 0.020 |
Why?
| | Echocardiography | 1 | 2012 | 642 | 0.020 |
Why?
| | Thyroid Function Tests | 1 | 2009 | 14 | 0.020 |
Why?
| | Elective Surgical Procedures | 1 | 2010 | 179 | 0.020 |
Why?
| | Cystatins | 1 | 2008 | 7 | 0.020 |
Why?
| | Myocardial Ischemia | 1 | 2010 | 263 | 0.020 |
Why?
| | ROC Curve | 1 | 2010 | 554 | 0.020 |
Why?
| | Cardiovascular Surgical Procedures | 1 | 2008 | 30 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2013 | 2486 | 0.020 |
Why?
| | Dobutamine | 1 | 2007 | 39 | 0.020 |
Why?
| | Angioplasty, Balloon, Coronary | 1 | 2008 | 141 | 0.020 |
Why?
| | Morbidity | 1 | 2008 | 324 | 0.020 |
Why?
| | Biomarkers, Tumor | 1 | 2013 | 1276 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2018 | 2069 | 0.020 |
Why?
| | Perioperative Care | 1 | 2008 | 178 | 0.020 |
Why?
| | Hemodynamics | 1 | 2011 | 1113 | 0.020 |
Why?
| | Exercise | 1 | 2018 | 2057 | 0.020 |
Why?
| | Electronic Health Records | 1 | 2013 | 1069 | 0.020 |
Why?
| | Rats | 1 | 2013 | 5647 | 0.010 |
Why?
| | Ventricular Function, Left | 1 | 2007 | 534 | 0.010 |
Why?
| | Genome-Wide Association Study | 1 | 2010 | 1431 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2016 | 5778 | 0.010 |
Why?
|
|
Chonchol's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|